Quercetin pretreated umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease via IL-10 /Janus kinase 2/STAT3 signaling

Figure 7 Therapeutic effects of quercetin-human umbilical cord-derived mesenchymal stem cells on inflammatory bowel disease mice continues until the recovery period, also through the interleukin 10 (IL-10), IL-6/Janus kinase/signal transducer and activator of transcription 3/suppressor of cytokine signaling 3 signaling pathways. A: Interleukin 10 (IL-10) mRNA expression in colon tissue through quantitative polymerase chain reaction (qPCR), ^cP < 0.05; B: Janus kinase 2 (JAK2) mRNA expression in colon tissue through qPCR, ^cP < 0.05; C: Signal transducer and activator of transcription 3 (STAT3) mRNA expression in colon tissue through qPCR, ^cP < 0.05; D: Detection of IL-10 and IL-6 protein expression through western blotting; E: Detection of JAK2, phosphorylated JAK2 (p-JAK2), STAT3, p-STAT3, and suppressor of cytokine signaling 3 (SOCS3) protein expression through western blotting; F: Semi-quantitative expression analysis of IL-10 proteins in colon tissue, ^dP < 0.01; G: Semi-quantitative expression analysis of IL-6 proteins in colon tissue, ^cP < 0.05; H: Semi-quantitative expression analysis p-JAK2 proteins in colon tissue, ^aP < 0.05, ^dP < 0.01; I: Semi-quantitative expression analysis of p-STAT3 proteins in colon tissue, ^aP < 0.05, ^dP < 0.01; J: Semi-quantitative expression analysis of SOCS3 proteins in colon tissue. The data are expressed as the mean ± SEM, n = 6. hUCMSCs: Human umbilical cord-derived mesenchymal stem cells; MSCs: Mesenchymal stem cells; QUR: Quercetin; TNBS: 2,4,6-trinitrobenzenesulfonic acid.